Erasca Shares Drop 48% After Patient Death in Early Cancer Drug Trial
Erasca (NASDAQ:ERAS) shares fell 48% after a patient death in its ERAS-0015 trial, raising safety concerns. The S&P 500 and Nasdaq Composite also declined, while peer Revolution Medicines saw a 10% rise. Analysts suggest the death may be a one-off case, not a widespread safety issue.
Topics: biotech clinical trials investor sentiment pharmaceuticals stock market